The following table shows the survival information of patients diagnosed with breast cancer at NCIS in 2018. The 5-year cancer-specific survival rate reflects the percentage of these patients who remain alive at the 5th year, according to their diagnosed breast cancer stage. Breast cancer demonstrates excellent survival outcomes across early stages at NCIS, with 100% survival for stage 0 disease and 98.3% for stage I. Stage II maintains strong survival at 94.9%, whilst stage III shows 80.5% survival. Advanced stage IV disease presents more challenging outcomes with 44.7% 5-year survival, reflecting the impact of metastatic disease on prognosis.
The following table shows the survival information of patients diagnosed with breast cancer at NCIS in 2018. The 5-year cancer-specific survival rate reflects the percentage of these patients who remain alive at the 5th year, according to their diagnosed breast cancer stage. Breast cancer demonstrates excellent survival outcomes across early stages at NCIS, with 100% survival for stage 0 disease and 98.3% for stage I. Stage II maintains strong survival at 94.9%, whilst stage III shows 80.5% survival. Advanced stage IV disease presents more challenging outcomes with 44.7% 5-year survival, reflecting the impact of metastatic disease on prognosis.
The following table shows the survival information of patients diagnosed with Diffuse Large B Cell Lymphoma (DLBCL) at NCIS in 2018. The 5-year cancer-specific survival rate reflects the percentage of these patients who remain alive at the 5th year, according to their diagnosed Diffuse Large B Cell Lymphoma (DLBCL) stage. DLBCL cancer demonstrates exceptional survival outcomes across localised and regional stages for patients treated at NCIS, with 100% survival for stage I, 71.4% for stage II, and 40 % for stage III. Even advanced stage IV disease maintains relatively favourable survival at 59.3 %, reflecting effectiveness of available treatments.
NCIS success rate for the Haematopoietic Stem Cell Transplant / Bone Marrow Transplant Programme is comparable to the international registry data at the Centre for International Blood & Marrow Transplant Research (CIBMTR) and the European Group for Blood and Marrow Transplant (EBMT).
| Type of transplant | Diseases | NCIS Survival Outcome | International Survival Outcome | References |
|---|---|---|---|---|
| Matched Sibling Donor (MSD) Transplant | Acute Leukaemia | ~50% at 5 years (2005 - 2016) | ~50% at 5 years (2001 - 2018), CIBMTR | Cheryl Lim, Koh LP et al. EBMT 2017 |
| Matched Unrelated (Volunteer) Donor (MUD) Transplant | Acute Leukaemia | ~50% at 5 years (2005 - 2016) | ~50% at 5 years (2001 - 2018), CIBMTR | Cheryl Lim, Koh LP et al. EBMT 2017 |
| Unrelated Umbilical Cord Blood (UCB) Transplant | Haematological Cancers | ~50% at 3 years (2007 - 2019) | ~40% at 5 years (2005 - 2016), EBMT | Ian Wu, Koh LP et al. ASH 2020. Ruggeri A, et al. Leukemia 2015. |
| Sequential Transplant Using Matched Related/Unrelated Donor | Haematological Cancers | ~60% at 3 years (2006 - 2020) | ~55% at 3 years (2007 - 2019) (EBMT) | Chong LL, Koh LP, et al. ASH 2020. Malard F, et al. BBMT 2017 |
| Haploidentical (mismatched related) donor transplant using Haplo-2017 Platform | Haematological Cancers | ~60% at 2 year (2012 - 2019) | 60% at 2 year (2012-2019), BMT-CTN 1101 study | Koh LP et al. BMT 2025. Koh LP et al. ASH 2022. Fuchs EJ et al. Blood 2021 |
References:
(Information is correct as at July 2022)
The following table shows the survival information of patients diagnosed with lung cancer at NCIS in 2018. The 5-year cancer-specific survival rate reflects the percentage of these patients who remain alive at the 5th year, according to their diagnosed lung cancer stage. Lung cancer demonstrates excellent survival for for patients treated at NCIS with early-stage disease with 97.2% survival for stage I. However, survival decreases substantially with advancing stage, showing 77.4% for stage II, 39.9% for stage III, and 16.5% for stage IV. These outcomes underscore the critical importance of early detection in lung cancer management.
The following table shows the survival information of patients diagnosed with prostate cancer at NCIS in 2018. The 5-year cancer-specific survival rate reflects the percentage of these patients who remain alive at the 5th year, according to their diagnosed prostate cancer stage. Prostate cancer demonstrates exceptional survival outcomes across localised and regional stages for patients treated at NCIS, with 100% survival for stage I, 97.4% for stage II, and 95.7% for stage III. Even advanced stage IV disease maintains relatively favourable survival at 43.8 %, reflecting effectiveness of available treatments.
